Clarithromycin/clofazimine/rifabutin - RedHill Biopharma
Alternative Names: Clarithromycin/rifabutin/clofazimine; Clofazimine/clarithromycin/rifabutin; Clofazimine/rifabutin/clarithromycin; Myoconda®; RHB 204; RHB-104; Rifabutin/clarithromycin/clofazimine; Rifabutin/clofazimine/clarithromycinLatest Information Update: 03 Jun 2024
At a glance
- Originator Centre for Digestive Diseases
- Developer RedHill Biopharma
- Class Anti-inflammatories; Antibacterials; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Aza compounds; Ethers; Macrolides; Phenazines; Piperidines; Rifamycins; Skin disorder therapies; Small molecules; Spiro compounds
- Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Crohn's disease; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
- No development reported Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus
- Discontinued Multiple sclerosis
Most Recent Events
- 03 Jun 2024 Discontinued - Phase-II for Multiple sclerosis in Israel (PO) (SEC File- 2023 - Redhill Biopharma)
- 31 Dec 2023 RedHill Biopharma terminates a phase-III clinical trials in Mycobacterium avium complex infections (Treatment-naive) in USA (PO) due to slow recruitment in the trial (NCT04616924) (SEC File- 2023 - Redhill Biopharma)
- 23 May 2023 RedHill Biopharma terminates a phase-III clinical trials in Nontuberculous mycobacterium (Treatment-naïve) infections in USA (PO)